25.04.2022 kl 07:45 7910

Fasten Seat Belts …. 👍

07:00 25.04.2022

Bergen, Norway, 25 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that it is presenting data today from its Phase IIa bemcentinib COVID-19 clinical trial (BCBC020) in a poster presentation at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held both online and in-person in Lisbon, Portugal, from April 23-26, 2022.

The poster presentation will share findings from the Company’s Phase IIa open label study of 115 patients evaluating bemcentinib in combination with Standard of Care (SoC) compared to a SoC control arm in the treatment of moderate to severe COVID-19 patients, immediately after hospital admission (BGBC020).

Clinical data from the study show that bemcentinib treatment (up to 14 days) confers early and sustained protection, limiting clinical deterioration in patients. Bemcentinib treated patients were discharged earlier from the hospital, required less supplementary oxygen and demonstrated a significant reduction in the need for intubation or ventilation.

Biomarker analysis demonstrates that treatment with bemcentinib reduced markers of acute inflammation and profibrotic cytokines, and increased expression of protective factors. These changes were more pronounced in patients with more serious disease, determined by high C-Reactive Protein (CRP) rates, high neutrophil to lymphocyte ratio (N/L) ratio or increased oxygen usage.

Preclinical data is also being presented from in vitro studies in lung epithelial cells on bemcentinib’s activity on variants of concern. These data suggest that bemcentinib inhibits infection of multiple SARS-CoV-2 variants, including Omicron, building on previous preclinical research from the Company.

Martin Olin, CEO of BerGenBio, commented: “The data we are presenting at ECCMID today further demonstrates the effectiveness of bemcentinib as a treatment for severe respiratory infections such as COVID-19. We have been pleased to see bemcentinib’s impact on reducing disease deterioration in patients. In addition, we’re encouraged to see that bemcentinib exerts a broad anti-inflammatory and pro-repair effect on blood biomarkers. We look forward to the initiation of the EUSolidAct platform trial which will further assess bemcentinib in hospitalised COVID-19 patients.”

Details of today’s poster presentation are as follows:

Abstract: 04778: Bemcentinib modulation of inflammatory, fibrotic and tissue repair pathways correspond with favourable clinical outcomes in hospitalised COVID-19 patients demonstrating higher severity cues: a biomarker perspective

Session Name: 12c. Clinical features, case management, outcome (incl long-term): programme no. L0383

Time, Location: Monday, 25th April 2022, 12:00pm - 13:00pm (WEST)
Redigert 25.04.2022 kl 07:47

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.